Literature DB >> 11065191

Interactions of metal ions with a 2,4-diaminopyrimidine derivative (trimethoprim). Antibacterial studies.

B Simó1, L Perelló, R Ortiz, A Castiñeiras, J Latorre, E Cantón.   

Abstract

The interaction of copper (II), zinc(II) and cadmium(II) with Trimethoprim (2,4-diamino-5-(3',4',5'-trimethoxybenzyl) pyrimidine) has been studied. The crystal structures of [Zn(Trim)2Cl2] (2) and [Cd(Trim)Cl2(CH3OH)]n (4) are reported. Compound (2) exhibits a distorted tetrahedral environment around the metal center and crystallizes in the triclinic space group P1 with a=10.2397(6), b=10.4500(6), c=16.3336(16) A, alpha=96.141(8), beta=106.085(5), gamma=96.551(5) degrees and Z=2. In complex (4), the Cd(II) centers are bridged sequentially by two chlorine ions to form infinite chains and present a six-coordinated environment; the compound crystallizes in the monoclinic P2(1)/C space group with a=13.958(5), b=7.532(2), c=18.390(2) A, alpha=90, beta=97.32(5), gamma=90 degrees and Z=4. In both structures the Trimethoprim acts as a monodentate ligand through the pyrimidinic nitrogen N(1) atom. The characterization of the Cu(Trim)2(CH3O)(ClO4) complex through EPR and magnetic measurements suggests a binuclear or polinuclear nature, with bridging methoxo groups. The complexes were screened for their activity against several bacteria, showing activity similar to that of trimethoprim.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11065191     DOI: 10.1016/s0162-0134(00)00118-5

Source DB:  PubMed          Journal:  J Inorg Biochem        ISSN: 0162-0134            Impact factor:   4.155


  2 in total

1.  Combination therapy of zinc and trimethoprim inhibits infection of influenza A virus in chick embryo.

Authors:  Magdi H El Habbal
Journal:  Virol J       Date:  2021-06-03       Impact factor: 4.099

2.  Synthesis, Characterization, and Antibacterial Studies of Pd(II) and Pt(II) Complexes of Some Diaminopyrimidine Derivatives.

Authors:  Peter A Ajibade; Omoruyi G Idemudia
Journal:  Bioinorg Chem Appl       Date:  2013-03-12       Impact factor: 7.778

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.